Before I begin, I feel it’s always important to point out I’m a shareholder of both NXEN and OWCP. In fact, most of my holdings are for more than a year (or two). I’m not offering investment advice and I have no intention of dumping my shares on unsuspecting/gullible investors by hyping/pumping. Though, if either stock runs over $500 million market cap — I may sell some shares at that point. You’ve been warned with as much honesty as the OTC as ever seen. ­čÖé

With that said, I want to point out that my title ‘Conviction to Hold‘ is from one of my favorite investors — Ian Cassel of MicroCapClub.com.

OWC Pharmaceutical Research Corp. (OTC: OWCP)

I wrote a blog back in July that talked about some ‘out-of-the-box due diligence’ that allowed for me to relax as I continued to hold onto my OWCP shares, as it continued down the rollercoaster. In a nutshell, I reached out to some truly legit cannabis (and pharma) companies and I was lucky enough to get a response from an awesome Canadian medical cannabis executive-type who was ironically traveling to Israel later that month. I helped arrange a meeting. The positive things he had to say about OWCP after meeting with them in Israel is what kept me calm.

I know that’s “extreme anecdotal” and I actually would NOT recommend you make Buy decisions based on something ‘some guy from the Internet’ said — including me. I’m simply telling you what I personally did to maintain my conviction to hold.

I was already feeling better and better about OWCP when they got Dr. Stanley Hirsch (Chairman), Yossi Dagan (CFO), and Dr. Zeevi (Chief Science Officer). I truly feel people like this (considering their previous employers/ventures) don’t join Scam Penny Stock companies.

On November 29th, 2018, OWCP had a press release that they “expect to complete the (Phase 1) trial by the end of December.” Following that, they announced being at MJBizCon (Las Vegas) and Biotech Showcase (San Francisco) to have one-on-one, face-to-face discussions with investors and potential partners. They also chose to reveal the testing of novel formulation of their Multiple Myeloma therapy in this PR. You’ll also notice the first mention of a new ‘Business Development’ contact, Miri Chen. (Hint? Miri was previously with Business Development for Rafa Labs, a pharmaceutical company that’s been around for 80 years.)

December 18th, 2018, OWCP announced the successful production of their Cannabinoid-enriched Sublingual Disintegrating Tablet. The studies will be conducted in Q1 of 2019 at a large hospital in Tel Aviv. (Hint, expect news about this study starting soon.)

It’s mid-January now, so I feel it’s getting to the point where “any day” OWCP could have their Phase 1 news / data out. After all, I never expected it to be immediately released. I also know from first hand experience that business deals take some time. It took a couple months of back-and-forth to sell my IT company.

The stock price currently sucks for people who have a much higher cost basis, but it’s pretty great for anybody who wants to start or add to a position. (I actually added at $0.108 on 12/26/2018.)

Nexien BioPharma (OTC: NXEN)

I’m surprised with this one. No, wait. I’m shocked. Baffled. I’ve watched so many junk stocks that are sometimes Dark/Defunct or have the Yield sign that run to unbelievably stupid and unrealistic market cap because they’re coming back to current to apparently get into the CBD business. I’ve watched ‘nothing’ companies with a “massive low float” of 93,000,000 shares run to stupid levels. I’ve watched a stock that had a multi-millionaire entrepreneur get onboard and it ran to beyond $1 BILLION market cap before they even updated shareholders on their ‘new direction’.

So, I repeat… I’m baffled when I see a company like Nexien BioPharma sinking lower and lower because, most likely, a private placement investor has been dumping his shares to move on. After all, these initial private placement investors wired money back in June and June 2017. Most OTC traders would have lost their mind having to hold from mid-2017 until October 22nd, 2018. So, maybe the dumping stops soon and people start discovering NXEN.

As of January 8th, 2019, NXEN had a confirmed float of 5,898,837. I e-mailed Brandy at Standard Registrar directly for this information.

November 26th, 2018, Alex Wasyl (CEO) was on Uptick Newswire doing an interview about the future of Nexien BioPharma. I highly recommend you listen to this interview for yourself if you’re thinking about buying shares. He’s well spoken. He’s intelligent.

November 28th, 2018, NXEN announced a collaboration with an Ivy League Medical School on pre-clinical cannabinoid studies. Once the study is underway, they will announce the name of said Ivy League school.

December 6th, 2018, NXEN releases a letter to shareholders to get everybody up to speed. They, again, talked about the CSE (Canadian Stock Exchange) listing as being an imminent catalyst. They’ve done all they can and now they must wait for the CSE to do their due diligence.

If you haven’t read my previous blogs on NXEN, I’ll say it again: The biggest reason I remain confident in the future of Nexien BioPharma is because of the line-up of advisors and management. Read the mini-biographies on the company website.

Noteworthy: Alain Bankier was a Board Member at “ebbu, inc.”, which was acquired by Canopy Growth (NYSE: CGC). He’s a known cannabis investor dating back well before the days of Nexien BioPharma. Watch this video interview. Robert Goldfarb and Accu-Break is a great connection for pharmaceuticals, as they have 50+ awarded patents. Dr. Joseph Aceto, PhD is an internal Legal & Intellectual Property expert, which saves the company a lot of cash expense. He is on the Board of Directors at the Pennsylvania Drug Discovery Institute. Jeremy Reeh had previously worked for Johnson & Johnson Pharmaceutical Research & Development. Lindy Snider is the daughter of a billionaire and founder of Lindi Skin. Kevin McGovern was a founder of SoBe Beverages, which sold to PepsiCo.

The list goes on and contains people from Pfizer, Novartis, Teva, and more.

So, again, it sucks to see $0.13 when I added as high as $0.60. The OTC is a bizarre place. Nexien BioPharma has virtually EVERYTHING a stock that runs wild would have — extremely tiny float, cannabinoid biopharma going the FDA route, Ivy League Medical School collaboration, and not just one bad-ass entrepreneur but a LINE-UP of successful entrepreneurs.

It’s my hope and honest opinion that it’s only a matter of time until both of these companies soar to Profitville.

As always, I hope you follow the links and conduct your own due diligence before you buy, hold, or sell. It’s your money and you MUST be comfortable with your investments. Good luck, every one.